+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Infantile Spasm Drug"

From
From
Global Infantile Spasms Therapeutics Market 2024-2028 - Product Thumbnail Image

Global Infantile Spasms Therapeutics Market 2024-2028

  • Report
  • December 2023
  • 154 Pages
  • Global
From
Infantile Spasm - Pipeline Insight, 2024 - Product Thumbnail Image

Infantile Spasm - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
From
From
From
Infantile Spasm - Epidemiology Forecast to 2032 - Product Thumbnail Image

Infantile Spasm - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
West Syndrome - Market Insight, Epidemiology and Market Forecast -2032 - Product Thumbnail Image

West Syndrome - Market Insight, Epidemiology and Market Forecast -2032

  • Drug Pipelines
  • January 2022
  • 200 Pages
  • Global
From
West Syndrome - Epidemiology Forecast - 2032 - Product Thumbnail Image

West Syndrome - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
  • 13 Results (Page 1 of 1)
Loading Indicator

Infantile Spasm (IS) is a rare neurological disorder that affects infants and young children. It is characterized by sudden, brief, and repetitive muscle contractions, usually in the form of jerking movements. Treatment for IS typically involves anticonvulsant drugs, such as vigabatrin, topiramate, and adrenocorticotropic hormone (ACTH). These drugs are used to reduce the frequency and severity of spasms, as well as to prevent further seizures. The Infantile Spasm Drug market is a subset of the Central Nervous System Drugs market. It is a small but growing market, driven by the increasing prevalence of IS and the need for effective treatments. The market is highly competitive, with a number of companies offering various drugs for the treatment of IS. Some of the major companies in the Infantile Spasm Drug market include Pfizer, Novartis, Sanofi, GlaxoSmithKline, and Merck. These companies offer a range of drugs for the treatment of IS, including vigabatrin, topiramate, and ACTH. Show Less Read more